There are 52 papers on estrogen receptor-positive breast cancer in aging research: 1 trial and 29 observational studies in people, 1 in animals, 19 reviews.
52 papers study it5 more mention it17 findings
4 new papers in 30 daysSee all 57 papers on estrogen receptor-positive breast cancer
“Receptor-specific analyses revealed positive associations with estrogen receptor-positive breast cancer (total and premenopausal).”
- Human trial1
- Humans29
- Animals1
- In silico2
Interventions
1Metformin
no changein humans1
1 study
Metformin
no changein humans1
Metformin was not clearly linked with estrogen receptor-positive breast cancer in humans (women with diabetes, subset with receptor data available).
Humanswomen with diabetes, subset with receptor data availablefemales
Upstream
3C-reactive protein
no changein humans1RR 1.03
1 study
C-reactive protein
no changein humans1RR 1.03
C-reactive protein was not clearly linked with estrogen receptor-positive breast cancer in humans (RR 1.03 (0.95, 1.11)).
Humansbloodfemalesn = 1,223
Sleep disorders
no changein humans1OR 0.98
1 study
Sleep disorders
no changein humans1OR 0.98
Sleep disorders were not clearly linked with estrogen receptor-positive breast cancer in humans (ER+ breast cancer) (OR 0.98, 95% CI 0.94-1.02, P = 0.304).
HumansER+ breast cancer
Age at menopause
mediatesin humans1−4.8% mediation proportion
1 study
Age at menopause
mediatesin humans1−4.8% mediation proportion
Age at menopause is linked with estrogen receptor-positive breast cancer in humans (mediation of the effect of polycystic ovary syndrome) (-4.82% mediation proportion).
Humansmediation of the effect of polycystic ovary syndrome
Associations
13TNF-alpha
no changein humans1RR 1.27
1 study
TNF-alpha
no changein humans1RR 1.27
TNF-alpha is associated with estrogen receptor-positive breast cancer in humans (RR: 1.27, 95% CI: 0.96, 1.68).
Humansbloodfemalesn = 1,223
Adiponectin
no changein humans1RR 1.1
1 study
Adiponectin
no changein humans1RR 1.1
Adiponectin is associated with estrogen receptor-positive breast cancer in humans (RR: 1.10, 95% CI: 0.90, 1.34).
Humansbloodfemalesn = 1,223
IL-10
upin humans1RR 1.14
1 study
IL-10
upin humans1RR 1.14
IL-10 is linked with a higher risk of estrogen receptor-positive breast cancer in humans (RR: 1.14, 95% CI: 1.01, 1.29).
Humansbloodfemalesn = 1,223
Leptin
upin humans1RR 1.13
1 study
Leptin
upin humans1RR 1.13
Leptin is linked with a higher risk of estrogen receptor-positive breast cancer in humans (RR: 1.13, 95% CI: 1.03, 1.25).
Humansbloodfemalesn = 1,223
Estrogen receptor-positive breast cancer polygenic risk score
upin humans1
1 study
Estrogen receptor-positive breast cancer polygenic risk score
upin humans1
Estrogen receptor-positive breast cancer polygenic risk score predicts estrogen receptor-positive breast cancer in humans (African ancestry) (AUC 0.621; external validation AUC 0.640).
HumansAfrican ancestryfemales
More on Estrogen receptor-positive breast cancer polygenic risk score
Reproductive senescence
upin mice1
1 study
Reproductive senescence
upin mice1
Reproductive senescence raises the risk of estrogen receptor-positive breast cancer in mice.
Animals
ESR1
upin mice1
1 study
ESR1
upin mice1
ESR1 raises the risk of estrogen receptor-positive breast cancer in mice (overexpression induced just before or with reproductive senescence).
Animalsoverexpression induced just before or with reproductive senescencemammary gland
Acrylamide
upin humans1
1 study
Acrylamide
upin humans1
Acrylamide is associated with estrogen receptor-positive breast cancer in humans (Total and premenopausal analyses).
HumansTotal and premenopausal analysesfemales
Age at menopause
upin humans1
1 study
Age at menopause
upin humans1
Age at menopause is associated with estrogen receptor-positive breast cancer in humans (also associated with ER- BC).
Humansalso associated with ER- BCfemales
Physical activity
downin humans1
1 study
Physical activity
downin humans1
Physical activity lowers the risk of estrogen receptor-positive breast cancer in humans (postmenopausal women).
Reviewpostmenopausal womenfemales
All 13Fewer
Trial sponsors
Company1 trialPhase 31,500 people
Company2 trialsPhase 2191 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 1221 people
Alliance for Clinical Trials in Oncology
2 trialsPhase 31,566 people
ETOP IBCSG Partners Foundation
1 trialPhase 33,066 people
1 trialPhase 3518 people
4 trialsPhase 2229 people
3 trialsPhase 2138 people
Latest
20 papers in 12 monthsEndocrine life after breast cancer: navigating hormonal challenges from treatment to survivorship
Type 1 Diabetes and Breast Cancer Risk: Evidence From an Updated Meta‐Analysis and Mendelian Randomization Study
Divergent Aging-Related Clinical Trajectories Associated with Aromatase Inhibitors and Tamoxifen in Older Breast Cancer Survivors
Inflammatory biomarkers and risk of postmenopausal oestrogen receptor-positive breast cancer: a case-cohort analysis
Association Between Sleep Disorders and Breast Cancer: An Analysis Based on NHANES and Mendelian Randomization
Sunlight Exposure and Breast Cancer Risk: A Systematic Review and Meta-analysis
See all 57 papers on estrogen receptor-positive breast cancer